Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Align Technology

DuPont de Nemours

ETRADE

FedEx

Marathon Oil

Tapestry

If you still own these stocks, watch out for more losses ahead.

Tax-loss selling leaves these losing stocks with more room to fall, Morgan Stanley says

Bank of America

Booz Allen Hamilton Hld

CVS Health

Chevron

CoreCivic

GEO Group

Alphabet

Gap Inc

Lockheed Martin

Northrop Grumman

Papa John's

Walgreens

Wells Fargo

Exxon Mobil

J.P. Morgan's list includes U.S. companies that would be affected by policy initiatives in areas like anti-trust, financial regulation, climate change, healthcare reform and minimum wage, among others.

These stocks could have the most to lose if a progressive Democratic agenda takes hold in 2020

Cigna (CI) is expanding its Medicare Advantage plans across states and counties along with supplemental benefits

Cigna Offers 2020 Medicare Plans with Supplemental Benefits

Humana

UnitedHealth Group

Shares of Humana Inc. HUM, -0.97% fell 1.0% in midday trading, to pace the declines in its health care-sector peers, after BMO Capital analyst Matt Borsch downgraded the health-care benefits plan company, citing a re-rating of companies given political and health policy uncertainty.

Humana, UnitedHealth downgraded while Cigna upgraded as part of hedge against health policy uncertainty

Anthem

Growth in government and pharmacy benefit management businesses as well as share buybacks should enhance the third-quarter earnings of health insurers.

3 Health Insurance Stocks Poised to Beat on Earnings in Q3

Cigna (CI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cigna (CI) Moves to Buy: Rationale Behind the Upgrade

Cigna (CI) expands the health care exchange plan to new regions beginning 2020 to enrich customer experience.

Cigna Expands Health Care Exchange Offerings to New Markets

Growth in health services, government business and international markets drive Cigna's (CI) stock.

Here's How Cigna (CI) is Poised Amid Political Uncertainty

After a solid earnings beat, Cigna still found itself returning to 52-week averages as negative sentiment puts pressure on the healthcare industry.

Cigna Still Solid Despite Negative Sentiment

AbbVie

Alexion Pharma

Bausch Health Companies Inc

Intercept Pharma

Johnson & Johnson

Eli Lilly

Pfizer

PRA Health Sciences

Eli Lilly, Alexion and AbbVie are just some of the top healthcare stocks to buy here, now that disappointing news has driven them to cheap prices.

10 Healthcare Stocks to Buy Despite the Headlines

Health insurer Cigna said on Thursday it had introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers.

Cigna rolls out new plan to fully cover multi-million dollar gene therapies

Cigna (CI) reported earnings 30 days ago. What's next for the stock?

Why Is Cigna (CI) Down 8.1% Since Last Earnings Report?

Cigna (CI) remains well poised for growth on the back of Express Scripts acquisition.

Here's Why Cigna (CI) is an Attractive Investment Option Now

Ally Financial

First Horizon National

Och-Ziff Capital Management

While several global economic and geopolitical concerns have led to sell-off in the finance stocks recently, the industry's fundamental strength and growth initiatives keep it poised for growth.

Are Investors Wrong in Selling These 4 Finance Stocks Now?

U.S. health insurer Cigna is exploring a sale of its group benefits insurance business, which could be valued at as much as $6 billion, four people familiar with the matter said on Tuesday.

Cigna seeks sale of group benefits insurance business, Reuters reports

U.S. health insurer Cigna Corp  is exploring a sale of its group benefits insurance business, which could be valued at as much as $6 billion, four people familiar with the matter said on Tuesday.

Exclusive: Cigna seeks sale of group benefits insurance business - sources

What Makes Cigna (CI) a New Buy Stock

Cigna Corporation (CI) CEO David Cordani on Q2 2019 Results - Earnings Call Transcript

Cigna's (CI) Q2 earnings gain from the acquisition of Express Scripts, completed in December 2018.

Cigna (CI) Beats on Q2 Earnings and Revenues, Guides Up

Cigna Corp. shares CI, -1.35% are up more than 3% in premarket trading Thursday after the insurer beat second-quarter earnings expectations and raised its forecast.

Cigna stock rises after earnings beat, raised outlook

Cigna Corp  reported a nearly 75% rise in quarterly profit on Thursday helped by a surge in revenue from its health services unit, which includes the Express Scripts pharmacy benefits business it acquired last year.

Cigna second-quarter profit rises 75%

Cigna's (CI) Q2 earnings should reflect increase in revenues from growth across its segments and share buyback.

Cigna (CI) to Report Q2 Earnings: What's in the Offing?

Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cigna (CI) to Report a Decline in Earnings: What to Look Out for

Cigna's (CI) Pharmacy Benefits management is poised to gain due to the pullback of the drug rebate proposal.

Cigna Stock Gains Near 9% on Drug Rebate Proposal Pullback

Chemours

Marathon Petroleum

Pure Storage

Six Flags

TripAdvisor

CNBC combed through Wall Street research over the last week to see which stocks analysts say to look at in the second half of the year.

News for Cigna Stock (CI)